Clinical Trials Search at Vanderbilt-Ingram Cancer Center
Avelumab or Hydroxychloroquine with or without Palbociclib for the Treatment of Stage II-III Breast Cancer, PALAVY Study
Breast
Breast
This phase II trial investigates the effect of avelumab or hydroxychloroquine sulfate with or without palbociclib in treating patients with stage II-III breast cancer that is positive for disseminated tumor cells (DTCs) after curative therapy. DTCs are breast cancer cells that are asleep (dormant) in the bone marrow. There are multiple ways in which these cells stay alive, and three of these mechanisms are inhibited by the drugs in this trial. First, dormant cancer cells need a protein signal pathway involving CDK 4/6 to start dividing once they wake up in order to survive as an active cancer cell. Palbociclib works by blocking the CDK 4/6 protein and by doing so may limit the dormant cancer cell from being able to survive. In addition, palbociclib may also help both of the other drugs in the trial to work better. Second, dormant cancer cells also use a process called autophagy to generate their own nutrition, which can allow them to stay asleep. Hydroxychloroquine has been shown to block autophagy, which leads to starvation of the cells. Third, dormant cancer cells are able to hide from the bodys immune system. The immune system sends a type of cell called T cells throughout the body to detect and fight infections and diseasesincluding cancers. One way the immune system controls the activity of T cells is through the PD-1/PD-L1 (programmed cell death protein-1) pathway. However, some cancer cells hide from T-cell attack by taking control of the PD-1/PD-L1 interaction and this stops T cells from attacking cancer cells. Avelumab is an antibody designed to block the PD-1/PD-L1 pathway and helps the immune system in detecting and fighting dormant cancer cells. Because palbociclib, hydroxychloroquine, and avelumab work on the mechanisms that keep the dormant cells alive, taking one or a combination of these drugs may be able to eliminate DTCs.
Breast
II
Reid, Sonya
NCT04841148
VICCBRE2161
Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease
Miscellaneous
Miscellaneous
This phase II trial studies how well acalabrutinib works in treating patients with chronic graft versus host disease. Acalabrutinib may be an effective treatment for graft-versus-host disease caused by a stem cell transplant.
Miscellaneous
II
Kitko, Carrie
NCT04198922
VICCCTT2122
Sparing Bone Marrow in Patients with Stage IIB-IV Lung Cancer, VMAT Trial
Lung
Lung
This phase II trial tests whether designing radiation to avoid bone marrow in the spine (vertebral bone marrow) leads to less reduction of white blood cell counts (lymphopenia) in patients with lung cancer. This sparing technique could lead to better disease control and outcome.
Lung
N/A
Osmundson, Evan
NCT05248256
VICCRAD2189
Contemporary Uro-Oncologic Specimen Protocol (CUSP)
Prostate
Prostate
Prostate
N/A
Tosoian, Jeffrey
VICCURO2226
The Use of Circulating Tumor DNA in the Monitoring and Treatment of Patients with Metastatic Colorectal Cancer and Liver Metastases
Multiple Cancer Types
Colon,
Liver
N/A
Eng, Cathy
VICCGI2239
Intraoral 3D Scanning of Head and Neck Resection Beds: a Feasibility Study.
Head/Neck
Head/Neck
Head/Neck
N/A
Topf, Michael
VICCHN2259
Virtual 3D Scanning and Intraoperative Communication System and Video Library for Head and Neck Surgical Specimens.
Head/Neck
Head/Neck
Head/Neck
N/A
Topf, Michael
VICCHN2272
MEASURE: Molecular evaluation of AML patients after stem cell transplant to understand relapse events.
Leukemia
Leukemia
Leukemia
N/A
Jayani, Reena
VICCCTT2284
Intraoperative identification and stimulation of the ANSA cervicalis.
Head/Neck
Head/Neck
Head/Neck
N/A
Kent, David
VICCHN2291